Publications by authors named "A A Sharathkumar"

Article Synopsis
  • The study investigates the effectiveness of enoxaparin, a medication for preventing blood clots, in critically ill children, focusing on differences in response based on age, particularly between older children and infants.
  • It consists of two simultaneous clinical trials: one for older children aged 1-17 years, and another for infants under 1 year, with specific dosing protocols for each group.
  • The trials are set in multiple pediatric intensive care units across the U.S., using methods like randomization, ultrasonography, and blood analysis to assess outcomes and monitor safety.
View Article and Find Full Text PDF

Inconsistencies in the definition of clinically unsuspected venous thromboembolism (VTE) in pediatric patients recently led to the recommendation of standardizing this terminology. Clinically unsuspected VTE (cuVTE) is defined as the presence of VTE on diagnostic imaging performed for indications unrelated to VTE in a patient without symptoms or clinical history of VTE. The prevalence of cuVTE in pediatric cancer patients is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the prevalence of vestibular disorders in patients with COVID-19 compared to those without the virus using data from the National COVID Cohort Collaborative database.
  • Results showed that individuals with COVID-19 were significantly more likely to experience vestibular disorders, with the highest risk associated with the omicron 23A variant (OR of 8.80).
  • The findings underscore the need for further research on the long-term effects of vestibular disorders in COVID-19 patients and implications for patient counseling.
View Article and Find Full Text PDF

Thrombopoietin receptor agonists (TPO-RAs) induce trilineage hematopoiesis under conditions with acquired hematopoietic failure. We evaluated safety, tolerability, and preliminary efficacy of a TPO-RA, romiplostim (Nplate), with or without standard-of-care immunosuppressive therapy (±IST) for children (ages < 21 y) with newly diagnosed and relapsed/refractory severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS). Data were collected from an observational study and a single arm interventional pilot study.

View Article and Find Full Text PDF